JANX - Janux Therapeutics gains amid renewed takevover speculation
2025-10-28 10:11:44 ET
More on Janux Therapeutics
- Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash
- Janux is a new Buy at Truist ahead of catalyst rich H2
- Piper Sandler initiates coverage of oncology companies
- Seeking Alpha’s Quant Rating on Janux Therapeutics
- Historical earnings data for Janux Therapeutics